Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyBlue Cross MA Prostatic Devices Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - MassachusettsPolicy 252

    Permanently Implanted Prostatic Devices for Benign Prostatic Hyperplasia

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 252 alerts

    Get alerted when Policy 252 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of permanently implanted prostatic stent devices used to treat lower urinary tract symptoms due to benign prostatic hyperplasia for eligible Commercial and Medicare HMO/PPO members, including investigational status, authorization requirements, and applicable procedure codes.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyPermanently Implanted Prostatic Devices for Benign Prostatic Hyperplasia
    Policy CodePolicy 252
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for inpatient services described in this policy.
    SourceLink
    POLICY UPDATE CHANGES

    A new medical policy establishes permanently implanted prostatic stent devices as investigational for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

    InvestigationalCoverage status

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    30.8%Legacy stent complication rate
    17.2%Legacy stent infection rate
    21,078Patients in cited analysis

    Coverage Criteria

    Permanently Implanted Prostatic Stents for BPH

    The technology is considered investigational.

    Investigational technology: Permanently implanted prostatic stent devices, including the ProVee System and Zenflow Spring Implant, are considered investigational for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

    The evidence is insufficient to determine that the technology improves the net health outcome.

    Permanently implanted prostatic stent devices, including the ProVee System and Zenflow Spring Implant, are considered investigational when used to treat lower urinary tract symptoms due to benign prostatic hyperplasia. Coverage may be denied because available evidence is insufficient to establish improvement in net health outcomes.

    Coding and Clinical Reference Criteria

    Investigational CPT CodesCPTExperimental
    0941TCystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization.
    0942TCystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold.
    0943TCystourethroscopy, flexible; with removal of prostatic urethral scaffold
    AUASI Symptom Severity
    Mild symptomsAUASI score ≤7
    Moderate symptomsAUASI score 8–19
    Severe symptomsAUASI score 20–35
    Moderate-to-Severe BPH Symptoms
    ThresholdAUASI score ≥8
    Severity categoryModerate-to-severe urinary symptoms
    Clinical contextFor patients with moderate-to-severe symptoms, bothersome symptoms, or both, discussion of medical therapy is reasonable.
    Zenflow Prostate Length Range
    Applicable prostate length25–45 mm
    DeviceZenflow Spring Implant
    Sizing purposeThe available implant sizes accommodate prostate lengths between 25 and 45 mm.
    Zenflow Implant Size Range
    Available implant length15–21 mm
    ConstructionPermanent nitinol spring coil constructed from a single wire strand.
    SizingAvailable in multiple sizes to accommodate prostate lengths between 25 and 45 mm.

    Authorization and Denial Guidance

    Prior Authorization

    Obtain inpatient precertification

    Precertification or preauthorization is required for all products when a service described in this policy is performed inpatient.

    Denial Risk

    Investigational devices may be denied

    Requests for permanently implanted prostatic stent devices, including the ProVee System and Zenflow Spring Implant, are subject to denial because the devices are considered investigational for lower urinary tract symptoms due to benign prostatic hyperplasia.

    Denial Risk

    Permanent prostatic stent coverage risk

    Clinical Background

    Benign prostatic hyperplasia (BPH) is an age-associated enlargement caused by hyperplastic tissue in the periurethral or transitional zone of the prostate. It can produce lower urinary tract symptoms, including increased urinary frequency, nocturia, urgency, hesitancy, weak urinary stream, urinary retention, incontinence, renal insufficiency, and urinary tract infection.

    Patients who have an inadequate response to medical therapy or experience significant adverse effects may be referred for surgical or ablative treatment. Permanently implanted prostatic stent devices are placed in the prostatic urethra and exert continuous radial expansion force to maintain luminal patency; they differ from temporary nitinol devices, which are removed after several days.

    Definitions

    Benign Prostatic Hyperplasia
    DefinitionA common disorder caused by hyperplastic nodules in the periurethral or transitional zone of the prostate.
    Relationship to LUTSThe condition produces lower urinary tract symptoms, including increased frequency, nocturia, urgency or hesitancy, and weak urinary stream.
    Potential progressionSymptoms may progress to acute urinary retention, incontinence, renal insufficiency, or urinary tract infection.
    Permanently Implanted Prostatic Stent Device
    DefinitionA device that remains implanted in the prostate and is designed to be retrievable if clinically warranted.
    MechanismExerts continuous radial expansion force against the prostatic lobes.
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyPermanently Implanted Prostatic Devices for Benign Prostatic Hyperplasia
    Policy CodePolicy 252
    Change TypeModified
    Effective DateOct 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or preauthorization for inpatient services described in this policy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical Reference CriteriaAuthorization and Denial GuidanceClinical BackgroundDefinitions

    Coverage may be denied when a permanently implanted prostatic stent device, including the ProVee System or Zenflow Spring Implant, is requested to treat lower urinary tract symptoms due to benign prostatic hyperplasia. The technology is considered investigational, and the evidence is insufficient to determine that it improves the net health outcome.

    PurposeMaintains luminal patency indefinitely.
    American Urological Association Symptom Index (AUASI)
    PurposeSelf-administered questionnaire assessing the severity of urinary symptoms.
    FormatSeven items.
    Total score range0–35
    Severity categoriesMild ≤7; moderate 8–19; severe 20–35.
    Permanently Implanted Prostatic Stent Devices
    DefinitionDevices permanently placed in the prostatic urethra.
    MechanismExert continuous radial expansion force to maintain luminal patency.
    Intended effectImprove urine outflow.
    Lower Urinary Tract Symptoms
    Associated conditionBenign prostatic hyperplasia.
    SymptomsIncreased urinary frequency, urgency, hesitancy, nocturia, and weak urinary stream.
    Clinical contextThese symptoms may be treated with permanently implanted prostatic stent devices intended to maintain prostatic urethral patency and improve urine outflow.
    Zenflow Spring Implant
    Device typePermanent nitinol spring coil implant.
    ConstructionMade from a single wire strand formed into ring elements connected by spine sections.
    Available configurationsMultiple sizes, 15–21 mm in length, to accommodate prostate lengths of 25–45 mm.
    Delivery systemDelivered through a proprietary single-use flexible cystoscope with an 11.5 Fr delivery catheter and balloon-anchored positioning system.